Journal of Clinical Pediatrics ›› 2020, Vol. 38 ›› Issue (8): 591-.doi: 10.3969/j.issn.1000-3606.2020.08.008

Previous Articles     Next Articles

A novel CLDN16 mutation in familial hypomagnesemia with hypercalciuria and nephrocalcinosis: a case report and literature review

LIN Jiao, FENG Chunyue, MAO Jianhua   

  1. Department of Nephrology, National Clinical Research Center For Child Health, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, Zhejiang, China
  • Online:2020-08-15 Published:2020-08-11

Abstract: Objective Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive genetic disease caused by CLDN16 or CLDN19 gene mutation. This paper is aimed to discuss the clinical characteristics and disease—causing mutations in FHHNC. Methods Clinical data of a patient with FHHNC was retrospectively analyzed. Results A two months old patient with hypomagnesemia and nephrocalcinosis in bilateral kidneys was admitted. The child had low blood magnesium and high urinary calcium; renal ultrasound indicated enhanced renal medullary echo, with repeated positive results of the urine cultures of Escherichia coli. Gene sequencing showed two heterozygous variants c.324+1G>C, c.317C>T in the CLDN16 gene (p.Ser106Phe). It was clinically improved after being treated orally with anti-infection and 25% magnesium sulfate, potassium magnesium aspartate, and 10% sodium citrate. Conclusion FHHNC is a rare disease with poor prognosis. At present, there is no special treatment except transplantation. Gene testing is helpful for early diagnosis of FHHNC.

Key words: familial hypomagnesemia with hypercalciuria and nephrocalcinosis; clinical characteristics; CLDN16 gene